Jayson Bedford
Stock Analyst at Raymond James
(4.00)
# 475
Out of 4,829 analysts
310
Total ratings
56.16%
Success rate
7.41%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICUI ICU Medical | Maintains: Strong Buy | $197 → $187 | $138.13 | +35.38% | 20 | May 9, 2025 | |
| MASI Masimo | Maintains: Outperform | $204 → $185 | $156.57 | +18.16% | 7 | May 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $119 → $104 | $95.21 | +9.23% | 8 | May 6, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $116 → $108 | $95.83 | +12.70% | 27 | Apr 25, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $142 | $133.24 | +6.57% | 28 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $154.22 | +6.34% | 23 | Apr 16, 2025 | |
| PODD Insulet | Reiterates: Outperform | $294 → $328 | $310.67 | +5.58% | 26 | Feb 21, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $102.86 | +18.61% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $536.51 | +28.24% | 8 | Jan 24, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $84.67 | +16.92% | 30 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $167.22 | +61.46% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $11.37 | +14.39% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.11 | +9.77% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $125.11 | +116.61% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.71 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.98 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $73.68 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.90 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $83.48 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.63 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $56.75 | +51.54% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.77 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.25 | - | 3 | Jan 2, 2018 |
ICU Medical
May 9, 2025
Maintains: Strong Buy
Price Target: $197 → $187
Current: $138.13
Upside: +35.38%
Masimo
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $156.57
Upside: +18.16%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $119 → $104
Current: $95.21
Upside: +9.23%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $116 → $108
Current: $95.83
Upside: +12.70%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $133.24
Upside: +6.57%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $154.22
Upside: +6.34%
Insulet
Feb 21, 2025
Reiterates: Outperform
Price Target: $294 → $328
Current: $310.67
Upside: +5.58%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $102.86
Upside: +18.61%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $536.51
Upside: +28.24%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $84.67
Upside: +16.92%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $167.22
Upside: +61.46%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $11.37
Upside: +14.39%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.11
Upside: +9.77%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $125.11
Upside: +116.61%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.71
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $22.98
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $73.68
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.90
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $83.48
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.63
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $56.75
Upside: +51.54%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.77
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $12.25
Upside: -